

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/024707 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/53 (2006.01) *C07F 9/6561* (2006.01)
A61K 31/675 (2006.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/US2024/039623

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

25 July 2024 (25.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/515,748 26 July 2023 (26.07.2023) US

(71) Applicant: **KINNATE BIOPHARMA INC.** [US/US];
12830 El Camino Real, Suite 150, San Diego, California
92130 (US).

(72) Inventors: **TYHONAS, John**; 12830 El Camino Real,
Suite 150, San Diego, California 92130 (US). **COX, Jason
M.**; 12830 El Camino Real, Suite 150, San Diego, Califor-
nia 92130 (US). **KANIA, Robert S.**; 12830 El Camino Re-
al, Suite 150, San Diego, California 92130 (US).

(74) Agent: **HEADRICK, Kyle M.** et al.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INHIBITORS OF CDK2/4/6 KINASE

(57) Abstract: Provided herein are inhibitors of CDK2/4/6 kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said CDK2/4/6 kinase inhibitory compounds for the treatment of disease.

WO 2025/024707 A1